Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Z Best Place to Talk Stocks -- Ignore unavailable to you. Want to Upgrade?

To: E.J. Neitz Jr who wrote (50204)	12/25/2003 5:49:48 PM
From: Triffin	Read Replies (1) \| Respond to of 53068

Possible SARS play ?? Saw this on the SARS thread, could have bullish implications for ITMN ( chart already strong )or could already be generally known .. thoughts ?? In a study published in today's Journal of the American Medical Association, Canadian researchers report SARS patients given a combination of steroids and interferon, an antiviral drug used to treat hepatitis C, were less likely to end up in intensive care than patients treated with steroids alone. They required less oxygen support and their lung infections cleared up faster. There were no side-effects to the treatment. The finding could have implications not just for the treatment of SARS, but also for the West Nile virus and even influenza, says lead researcher Dr. Eleanor Fish. stockcharts.com Triffin